The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
Abstract
PURPOSE: To compare two doses of letrozole and megestrol acetate (MA) as second-line therapy in postmenopausal women with advanced breast cancer previously treated with antiestrogens. PATIENTS AND METHODS: Five hundred fifty-one patients with locally advanced, locoregionally recurrent or metastatic breast cancer were randomly assigned to receive letrozole 2.5 mg (n = 174), letrozole 0.5 mg (n = 188), or MA 160 mg (n = 189) once daily in a double-blind, multicenter trial. Data were analyzed for tumor response and safety variables up to 33 months of follow-up evaluation and for survival up to 45 months. RESULTS: Letrozole 2.5 mg produced a significantly higher overall objective response rate (24%) compared with MA (16%; logistic regression, P = .04) or letrozole 0.5 mg (13%; P = .004). Duration of objective response was significantly longer for letrozole 2.5 mg compared with MA (Cox regression, P = .02). Letrozole 2.5 mg was significantly superior to MA and letrozole 0.5 mg in time to treatment failure (P = .04 and P = .002, respectively). For time to progression, letrozole 2.5 mg was superior to letrozole 0.5 mg (P = .02), but not to MA (P = .07). There was a significant dose effect in overall survival in favor of letrozole 2.5 mg (P = .03) compared with letrozole 0.5 mg. Letrozole was significantly better tolerated than MA with respect to serious adverse experiences, discontinuation due to poor tolerability, cardiovascular side effects, and weight gain. CONCLUSION: The data show letrozole 2.5 mg once daily to be more effective and better tolerated than MA in the treatment of postmenopausal women with advanced breast cancer previously treated with antiestrogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endocrine treatment of breast cancer in women
SANTEN, R. J., MANNI, A., HARVEY, H., & REDMOND, C. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-2-221 · Cited by 399
Jonat, W., Howell, A., Blomqvist, C., Eiermann, W., Winblad, G., Tyrrell, C., Mauriac, L., Roche, H., Lundgren, S., Hellmund, R., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00014-3 · Cited by 254
Bhatnagar, A. S., Häusler, A., Schieweck, K., Lang, M., & Bowman, R. (1990) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(90)90460-3 · Cited by 246
Dowsett, M., Jones, A. L., Johnston, S. R. D., Jacobs, S., Trunet, P. F., & Smith, I. E. (1995) · PubMed · Cited by 238
Self-citationBuzdar, A. U., Jones, S. E., Vogel, C. L., Wolter, J., Plourde, P., Webster, A., & for the Arimidex Study Group (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970215)79:4<730::aid-cncr10>3.0.co;2-0 · Cited by 207
The EORTC Core Quality-of-Life Questionnaire: Interim Results of an International Field Study *
Aaronson, N. K., Ahmedzai, S. H., Bullinger, M., Crabeels, D., Estapé, J., Filiberti, A., Flechtner, H., Frick, U., Hürny, C., Kaasa, S., et al. (2021) · CRC Press eBooks · doi:10.1201/9781003068648-14 · Cited by 157
Evans, T. R. J., di Salle, E., Ornati, G., Lassus, M., Benedetti, M. S., Pianezzola, E., & Coombes, R. C. (1992) · PubMed · Cited by 149
(1993) · PubMed · Cited by 130
Buzdar, A. U., Smith, R. A., Vogel, C. L., Bonomi, P., Keller, A. M., Favis, G., Mulagha, M. T., Cooper, J., & for the Multi-Institutional Trialist Collaborative Study Group (1996) · Cancer · Cited by 118
Howell, A., Mackintosh, J., Jones, M., Redford, J., Wagstaff, J., & Sellwood, R. A. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90046-6 · Cited by 106
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women
Iveson, T. J. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.77.2.324 · Cited by 82
Bisagni, G., Cocconi, G., Scaglione, F., FRASCHINI, F., Pfister, C., & Trunet, P. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010490 · Cited by 74
Self-citationMuss, H. B., Case, L. D., Capizzi, R. L., Cooper, M. R., Cruz, J. M., Jackson, D. V., Richards, F., Powell, B. L., Spurr, C. L., & White, D. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.11.1797 · Cited by 73
Robertson, J. F. R., Williams, M. R., Todd, J. H., Nicholson, R. I., Morgan, D. A. L., & Blamey, R. W. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90259-9 · Cited by 72
Trunet, P., Mueller, P., Bhatnagar, A. S., Dickes, I., Monnet, G., & White, G. E. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.77.2.8345034 · Cited by 69
Self-citationWillemse, P. H. B., Ploeg, E. V. D., Sleijfer, D. T., Tjabbes, T., & van Veelen, H. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90231-h · Cited by 54
Self-citationInhibition of Aromatase in Vitro and in Vivo by Aromatase Inhibitors
Bhatnagar, A. S., Häusler, A., & Schieweck, K. (1990) · Journal of enzyme inhibition · doi:10.3109/14756369009040740 · Cited by 34
Lee, K. L., Macaulay, V. M., Nicholls, J., DETRE, S. I., Ashworth, A., & Dowsett, M. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620311 · Cited by 26
Aromatase Inhibitors in Malignant Diseases of Aging
Johannessen, D. C., & Lønning, P. E. (1992) · Drugs & Aging · doi:10.2165/00002512-199202060-00008 · Cited by 14
Tominaga, T., Ohashi, Y., Abe, R., Yoshida, M., Koyama, H., Nomura, Y., & Bhatnagar, A. S. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)95626-h · Cited by 12
Lipton (1995) · Pure Amsterdam UMC · doi:10.1002/1097-0142(19950415)75:8 · Cited by 1
Cited by
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Winer, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R., Edge, S. B., Gralow, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,031
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jänicke, F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2596 · Cited by 1,015
Nabholtz, J. M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 992
Aromatase Inhibitors in Breast Cancer
Smith, I. E., & Dowsett, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023246 · Cited by 905
Self-citation
Metadata
- Authors
- Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Morgan, M., Fornasiero, A., Hoffmann, W., Michel, J., Hatschek, T., Tjabbes, T., Chaudri, H. A., Hornberger, U., & Trunet, P. F.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-02
- Volume
- 16
- Issue
- 2
- Pages
- 453-461
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1934173384
- Cited by
- 638
- References
- 21
- FWCI
- 20.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.